Xoma Halts Acne Therapy XMP.629 Development, Will Evaluate BPI Program
This article was originally published in Pharmaceutical Approvals Monthly
Xoma is evaluating all of its existing bactericidal/ permeability increasing protein (BPI) programs in the wake of "inconclusive" Phase II results for the acne treatment XMP.629, the company said.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class